Immuno-Oncology Diagnostics Market Forecasts with COVID-19 Impacts and Updates Including Executive/Consultant Guides with Customized Forecasting and Analysis 2021 to 2025
“Explosion in immuno-oncology therapies creates an exploding diagnostic market. What is the impact of COVID-19?”
Revolution in cancer therapy to be driven by new diagnostics. Histology, genomics and liquid biopsy converge. COVID-19 changes the focus of research.
A revolution in cancer therapy is underway. New therapy based on using the body’s natural immune defenses is having unprecedented success. However diagnostics, especially biomarkers are desperately needed to help select the right therapy.
This is a complex field and this readable report will bring company management teams up to speed on both technology and the opportunity, and the surprising impact of COVID-19 on what might seem to be an unrelated area.
Tumor Mutational Burden (TMB)? Checkpoint Inhibitors? Cytokines? Find out about the technology in readily understood terms that explain the jargon. Find the opportunities and the pitfalls. Understand growth expectations and the ultimate potential market size.
Subscribe and Save
By signing up for the annual subscription, updates to this report will be automatically provided free of charge for a period of one year from initial purchase. These updates can include revised forecasts as markets increase or contract and exclusive market commentary not seen anywhere else. With the effects of COVID-19 being felt across all markets it has never been more crucial to stay fully informed with real-world actionable data. Subscribe to this report and receive ongoing market forecasting and analysis for sharpened strategic planning throughout the year.
- Quarterly report updates
- Summary of significant developments and market changes
- Phone consultation and assistance on request for the duration of the subscription
Our research makes you the expert in your organization. Get our research team working for you by ordering this comprehensive report. Check all your licensing options, however your order is available as a credit if you wish to upgrade. We wrote this report and are ready by phone or email to help you use it.
Assistance and additional breakout data relevant to your own area(s) of interest is available free of charge with the corporate license.
ABOUT THE LEAD AUTHOR
Mr. Greg Powell, B.SC., M.B.A is an experienced business and clinical professional. He is co-author of the paper "The Radioimmunoassay of Angiotensinogen by Antibody Trapping." He has worked in laboratory testing and management for over 20 years. Mr. Powell’s education includes:
- B.Sc. (Chemistry) University of BC
- M.B.A. (Finance and Policy) University of BC
- Market Research Seminar - Burke Institute
- Finance for Senior Executives - Harvard Business School